Mometasone furoato 0.1% in monoapplicazione giornaliera nella dermatite allergica da contatto e nella dermatite atopica: Studio controlato verso betametasone valerato

Translated title of the contribution: Mometasone furoate 0.1% once a day in allergic contact dermatitis and in atopic dermatitis: Controlled study versus betamethasone valerate

P. L. Amerio, P. Biggio, G. Bossi, T. Cainelli, P. Cappugi, D. Cerimele, G. Rabbiosi, M. Cespa, F. Galla, G. Landi, F. Rantuccio, A. Sapuppo, C. Veller Fornasa, L. Stingeni

Research output: Contribution to journalArticle

Abstract

The aim of the study is to compare clinical efficacy and safety mometasone furoate (MF) versus betamethasone valerate (BV) in allergic contact dermatitis and in atopic dermatitis. This multicentric, single blind, randomised, parallel group trial was diagnosis stratified. Thirteen dermatological centres (University Departments or Hospital Divisions), homogeneously distributed in Italy, were involved. One hundred two allergic patients (age 37.9 years) and 97 atopic patients (age 19.5 years) were admitted. The extension of the treated lesions, which were exacerbating for at least one week, was less than 10% of the total body surface. MF was applied once a day while BV was applied twice; the treatment period lasted maximum for 15 days. At the baseline, after 3, 7 days and at the end of the treatment, a severity score of erythema, oedema/essudate, scaling, excoriation, lichenification (objective symptoms) and pruritus and burning (subjective symptoms), was made. The treatment of allergic contact dermatitis lasted 13.7 ± 3.3 days (mean ± SD) in MF group and 13.8 ± 2.7 days (mean ± SD) in BV group. The results show that MF and BV are highly effective in both kind of the studied dermatitis with no significant differences between the two treatment groups. By the end of the treatment, in the allergic contact dermatitis group, 88.2% and 87.6% reduction (no statistically significant, Mann Whitney), of the total score concerning objective symptoms was seen for MF and BV respectively; in the atopic dermatitis group, 83.1% (MF) and 89.2% (BV) reduction was seen (no statistically significant, Mann Whitney). Neither dermatological adverse experiences (such as skin atrophy) nor other adverse events were recorded. MF applied once a day, compared to BV applied twice a day, allows to save the amount of steroid drugs used and therefore a lower exposure to their potential adverse systemic or cutaneous effects.

Translated title of the contributionMometasone furoate 0.1% once a day in allergic contact dermatitis and in atopic dermatitis: Controlled study versus betamethasone valerate
Original languageItalian
Pages (from-to)255-260
Number of pages6
JournalDermatologia Clinica
Volume18
Issue number4
Publication statusPublished - Oct 1998

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Mometasone furoate 0.1% once a day in allergic contact dermatitis and in atopic dermatitis: Controlled study versus betamethasone valerate'. Together they form a unique fingerprint.

  • Cite this

    Amerio, P. L., Biggio, P., Bossi, G., Cainelli, T., Cappugi, P., Cerimele, D., Rabbiosi, G., Cespa, M., Galla, F., Landi, G., Rantuccio, F., Sapuppo, A., Veller Fornasa, C., & Stingeni, L. (1998). Mometasone furoato 0.1% in monoapplicazione giornaliera nella dermatite allergica da contatto e nella dermatite atopica: Studio controlato verso betametasone valerato. Dermatologia Clinica, 18(4), 255-260.